Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Constipation Clear all
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 10, 2026, 2:01 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Preop Laxatives in Robotic Urologic Surgery

NCT05805436
View directory record Official record
Conditions
Prostate Cancer, Kidney Cancer, Constipation
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
Chad R. Tracy
Other
Eligibility
30 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jun 10, 2026, 2:01 AM EDT
Completed No phase listed Observational

Fecal Calprotectin Collection Protocol

NCT03143517
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Indeterminate Colitis, Chronic Diarrhea, Celiac Disease, Diverticulitis, Abdominal Pain, Distension, Weight Loss, Food Intolerance, Constipation
Interventions
Stool collection
Diagnostic Test
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
4 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Dothan, Alabama • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

NCT04026113
View directory record Official record
Conditions
Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
79
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability and Functional Assessment of a Novel Children's Synbiotic

NCT04534036
View directory record Official record
Conditions
Constipation, Signs and Symptoms, Digestive Signs and Symptoms, Infrequent or Difficult Evacuation
Interventions
PDS-08, Placebo
Dietary Supplement · Other
Lead sponsor
Seed Health
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jun 10, 2026, 2:01 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

NCT00583128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
AST-120, Celphere® CP-305
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

Effect of TU-100 in Patients With Functional Constipation

NCT01348152
View directory record Official record
Conditions
Functional Constipation
Interventions
DAIKENCHUTO (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Jun 10, 2026, 2:01 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Multistrain Probiotic for Functional Constipation

NCT01618617
View directory record Official record
Conditions
Functional Constipation
Interventions
High dose Multistrain probiotic, 100 billion cfu/day, Low dose Multistrain probiotic, 15 billion cfu/day
Dietary Supplement
Lead sponsor
Renew Life Formulas Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial

NCT00779493
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
curcumin, placebo
Dietary Supplement
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jun 10, 2026, 2:01 AM EDT
Terminated Phase 3 Interventional

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

NCT00171431
View directory record Official record
Conditions
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jun 10, 2026, 2:01 AM EDT
Withdrawn Not applicable Interventional

Functional Magnetic Stimulation Enhances Gastrointestinal Motility in Patients With Chronic Constipation

NCT01786837
View directory record Official record
Conditions
Constipation
Interventions
Functional Magnetic Stimulation
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Not applicable Interventional

Impact of Defecation Posture on Ease of First Bowel Movement Following Posterior Repair

NCT06253689
View directory record Official record
Conditions
Postoperative Constipation, Pelvic Organ Prolapse Vaginal Surgery, Defecation Function
Interventions
Defecation Posture Modification Device
Device
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Neostigmine and Glycopyrrolate

NCT04027972
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 2:01 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 2:01 AM EDT
Enrolling by invitation No phase listed Observational

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jun 10, 2026, 2:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomarkers for Intestinal Permeability in Patients With Constipation

NCT02246647
View directory record Official record
Conditions
Intestinal Diseases, Irritable Bowel Syndrome, Constipation
Interventions
Permeability measurement, Esophagogastroduodenoscopy, Flexible sigmoidoscopy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

NCT05652205
View directory record Official record
Conditions
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions
Placebo for Linaclotide, Linaclotide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 2:01 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 10, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers

NCT06570668
View directory record Official record
Conditions
Constipation - Functional
Interventions
CDD-2101
Drug
Lead sponsor
Centre for Chinese Herbal Medicine Drug Development Limited
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jun 10, 2026, 2:01 AM EDT
Recruiting Phase 2Phase 3 Interventional

Home Transcutaneous Electrical Acustimulation (TEA)

NCT05519683
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
TEA, Lexapro
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 10, 2026, 2:01 AM EDT